Orchestra BioMed Holdings, Inc.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $33.5M
- Net income
- -$52.7M
- Total assets
- $114.9M
- Market cap
- $233.5M
- Gross margin
- 99.4%
- Operating margin
- -154.7%
- Net margin
- -157.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $33.5M
- Cost of revenue
- $190.0K
- Gross profit
- $33.3M
- Operating expenses
- $85.1M
- Operating income
- -$51.8M
- Income tax
- $0
- Net income
- -$52.7M
- EPS (basic)
- $-1.11
- EPS (diluted)
- $-1.11
Balance sheet
- Total assets
- $114.9M
- Current assets
- $107.9M
- Total liabilities
- $51.5M
- Current liabilities
- $16.7M
- Shareholders’ equity
- $53.6M
Cash flow
- Operating cash flow
- -$49.0M
- Investing cash flow
- -$26.9M
- Financing cash flow
- $88.3M
- Net cash flow
- $12.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $233.5M
- EPS (diluted)
- $-1.11
- Shares outstanding
- 59.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 27, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $52.7M in FY2025.
- Revenue grew 1113% from FY2023 to FY2025.
- Gross margin of 99.4%, net margin -157.4%.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Orchestra BioMed Holdings, Inc..
Write a review
News about Orchestra BioMed Holdings, Inc.
News & sentiment via Polygon.io
